Downregulation of the cardiotrophin-1 gene expression by valsartan and spironolactone in hypertrophied heart rats in vivo and rat cardiomyocyte H9c2 cell line in vitro: A novel mechanism of cardioprotection

Journal of Cardiovascular Pharmacology

Volumn 61, Issue 4, 2013, Pages 337-344

  Al Mazroua, Haneen A ^a   Al Rasheed, Nawal M ^a   Korashy, Hesham M ^a  

^a KING SAUD UNIVERSITY   (Saudi Arabia)

Author keywords

cardiotrophin 1; H9c2; heart failure; hypertrophic gene; isoproterenol; spironolactone; valsartan

Indexed keywords

ATRIAL NATRIURETIC FACTOR; CARDIOTROPHIN 1; CREATINE KINASE; DACTINOMYCIN; ISOPRENALINE; MESSENGER RNA; SPIRONOLACTONE; VALSARTAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CARDIOTOXICITY; CONTROLLED STUDY; DOWN REGULATION; GENE EXPRESSION; HEART HYPERTROPHY; HEART PROTECTION; HEART WEIGHT; IN VITRO STUDY; IN VIVO STUDY; MALE; MYOBLAST; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; REAL TIME POLYMERASE CHAIN REACTION; TREATMENT DURATION; WESTERN BLOTTING;

ANIMALS; BLOTTING, WESTERN; CARDIOMEGALY; CARDIOTONIC AGENTS; CELL LINE; CYTOKINES; DISEASE MODELS, ANIMAL; DOWN-REGULATION; HEART FAILURE; ISOPROTERENOL; MALE; MYOCYTES, CARDIAC; RATS; RATS, WISTAR; REAL-TIME POLYMERASE CHAIN REACTION; RNA, MESSENGER; SPIRONOLACTONE; TETRAZOLES; VALINE;

EID: 84876413810     PISSN: 01602446     EISSN: 15334023     Source Type: Journal    
DOI: 10.1097/FJC.0b013e318283a565     Document Type: Article

References (37)

1. Miyake T, Alli NS, Aziz A, Knudson J, et al. Cardiotrophin-1 maintains the undifferentiated state in skeletal myoblasts. J Biol Chem. 2009;284: 19679-19693
2. Cripps RM, Zhao B, Olson EN. Transcription of the myogenic regulatory gene Mef2 in cardiac, somatic, and visceral muscle cell lineages is regulated by a Tinman-dependent core enhancer. Dev Biol. 1999;215:420- 430
3. Yoshida K, Taga T, Saito M, et al. Targeted disruption of gp130, a common signal transducer for the interleukin 6 family of cytokines, leads to myocardial and hematological disorders. Proc Natl Acad Sci U S A. 1996;93:407-411
4. Takimoto Y, Aoyama T, Iwanaga Y, et al. Increased expression of cardiotrophin-1 during ventricular remodeling in hypertensive rats. Am J Physiol Heart Circ Physiol. 2002;282:896-901
5. Zolk O, Engmann S, Munzel F, et al. Chronic cardiotrophin-1 stimulation impairs contractile function in reconstituted heart tissue. Am J Physiol Endocrinol Metab. 2005;288:E1214-E1221
6. Jougasaki M, Tachibana I, Luchner A, Leskinen H, et al. Augmented cardiac cardiotrophin-1 in experimental congestive heart failure. Circulation. 2000;101:14-17
7. Lopez B, González A, Querejeta R, Barbra J, et al. Association of plasma cardiotrophin-1 with stage C heart failure in hypertensive patients: Potential diagnostic implications. J Hypertens. 2009;27:418-424
8. Eisenberg MJ, Gioia LC. Angiotensin II receptor blockers in congestive heart failure. Cardiol Rev. 2006;14:26-34
9. Cohn JN, Togoni G; Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med. 2001;345:1667-1675
10. Dieterich HA, Wendt C, Saborowski F. Cardioprotection by aldosterone receptor antagonism in heart failure. Part I. The role of aldosterone in heart failure. Fiziol Cheloveka. 2005;31:97-105
11. Thai H, Guarraia D, Johnson N, et al. Valsartan therapy in heart failure after myocardial infarction: The role of endothelial dependent vasorelaxation. J Cardiovasc Pharmacol. 2007;50:703-707
12. Cittadini A, Monti MG, Isgaard J, Casaburi C, et al. Aldosterone receptor blockade improves left ventricular remodeling and increases ventricular fibrillation threshold in experimental heart failure. Cardiovasc Res. 2003; 58:555-564
13. Zordoky BN, Aboutabl ME, El-Kadi AO. Modulation of cytochrome P450 gene expression and arachidonic acid metabolism during isoproterenolinduced cardiac hypertrophy in rats. Drug Metab Dispos. 2008;36: 2277-2286
14. Jenkins DJ. An investigation into creatine kinase and other plasma enzymes in thyroid disorders. Clin Chim Acta. 1978;85:197-204
15. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001;25:402-408
16. Sambrook J, Fritsch EF, Maniatatis T. 2nd. In: Ford N, ed. Molecular Cloning. A Laboratory Manual. Plainview, NY: Cold Spring Harbour Laboratory Press; 1989;1.63-1.70
17. Korashy HM, El-Kadi AO. Differential effects of mercury, lead and copper on the constitutive and inducible expression of aryl hydrocarbon receptor (AHR)-regulated genes in cultured hepatoma Hepa 1c1c7 cells. Toxicology 2004;201:153-172
18. Korashy HM, El-Kadi AO. The role of aryl hydrocarbon receptor and the reactive oxygen species in the modulation of glutathione transferase by heavy metals in murine hepatoma cell lines. Chem Biol Interact. 2006; 162:237-248
19. López-Andrés N, Iñigo C, Gallego I, Díez J, et al. Aldosterone induces cardiotrophin-1 expression in HL-1 adult cardiomyocytes. Endocrinology. 2008;149:4970-4978
20. Liu JJ, Li DL, Zhou J, Sun L, et al. Acetylcholine prevents angiotensin II-induced oxidative stress and apoptosis in H9c2 cells. Apoptosis. 2011; 16:94-103
21. Ruskoaho H. Atrial natriuretic peptide: Synthesis, release, and metabolism. Pharmacol Rev. 1992;44:479-602
22. Comini L, Agnoletti G, Panzali A, Mantero G, et al Activation of ANP synthesis during congestive heart failure in rats treated with monocrotaline. Am J Physiol. 1995;268:391-398
23. Liu B, Li W, Li Y, Wang Z, et al. Protective effects of N-acetylcysteine in isoproterenol-induced myocardium injury in rats. Mol Biol Rep. 2009; 36:761-765
24. Janjua S, Lawrence KM, Ng LL, Latchman DS. The cardioprotective agent urocortin induces expression of CT-1. Cardiovasc Toxicol. 2003; 3:255-256
25. López N, Díez J, Fortuño MA. Characterization of the protective effects of cardiotrophin-1 against non-ischemic death stimuli in adult cardiomyocytes. Cytokine. 2005;30:282-292
26. Tsutamoto T, Wada A, Maeda K, Mabuchi N, et al. Effect of spironolactone on plasma brain natriuretic peptide and left ventricular remodeling in patients with congestive heart failure. J Am Coll Cardiol. 2001;37: 1228-1233
27. Tachikawa H, Kodama M, Hui L, Yoshida T, et al. Angiotensin II type 1 receptor blocker, valsartan, prevented cardiac fibrosis in rat cardiomyopathy after autoimmune myocarditis. J Cardiovasc Pharmacol. 2003;41:105-110
28. Zhang YJ, Bai XJ, Qi ZM, Wang HX. Mechanism of cardioprotection against ischemia/reperfusion injury by valsartan: An experiment with isolated rat hearts [Article in Chinese]. Zhonghua Yi Xue Za Zhi. 2005; 85:3350-3353
29. Goyal BR, Solanki N, Goyal RK, Mehta AA. Investigation into the cardiac effects of spironolactone in the experimental model of type 1 diabetes. J Cardiovasc Pharmacol. 2009;54:502-509
30. Fukuzawa J, Booz GW, Hunt RA, Shimizu N, et al. Cardiotrophin-1 increases angiotensinogen mRNA in rat cardiac myocytes through STAT3: An autocrine loop for hypertrophy. Hypertension. 2000;35: 1191-1196
31. Wollert KC, Taga T, Saito M, Narazaki M, et al. Cardiotrophin-1 activates a distinct form of cardiac muscle cell hypertrophy. Assembly of sarcomeric units in series VIA gp130/leukemia inhibitory factor receptordependent pathways. J Biol Chem. 1996;271:9535-9545
32. Wu Y, Liu J. Simvastatin attenuated cardiac hypertrophy via inhibiting JAK-STAT pathways [Article in Chinese]. Zhonghua Xin Xue Guan Bing Za Zhi. 2008;36:738-743
33. Liu J, Liu Z, Huang F, Xing Z, et al. Pioglitazone inhibits hypertrophy induced by high glucose and insulin in cultured neonatal rat cardiomyocytes. Pharmazie. 2007;62:925-929
34. Lopez N, Díez J, Fortuño MA. Differential hypertrophic effects of cardiotrophin-1 on adult cardiomyocytes from normotensive and spontaneously hypertensive rats. J Mol Cell Cardiol. 2006;41:902-913
35. Kimes BW, Brandt BL. Properties of a clonal muscle cell line from rat heart. Exp Cell Res. 1976;98:367-381
36. Chen QM, Tu VC, Wu Y, Bahl JJ. Hydrogen peroxide dose dependent induction of cell death or hypertrophy in cardiomyocytes. Arch Biochem Biophys. 2000;373:242-248
37. Sobell HM. Actinomycin and DNA transcription. Proc Natl Acad Sci U S A. 1998;82:5328-5331